General Electric Company

Abbott Laboratories Corporation

Affibody Ab

Rong Zhang

Faisal Ahmed Syud

Todd Warren Rockway

David A Betebenner

Dale J Kempf

Rolf Wagner

Allan C Krueger

Tami J Pilot-Matias

Curt S Cooper

Darold L Madigan

Jack Mathew Webster

David D Anderson

Brian Duh-Lan Lee

Paul Schaffer

Liangjun Lu

Robert J Carrick

Clarence J Maring

Michael D Tufano

Christopher E Motter

Elin Gunneriusson

Jason P Shanley

John K Pratt

Dachun Liu

Keith F McDaniel

Pamela L Donner

Michael James Rishel

Lars B Abrahmsen

Joachim Feldwisch

Fredrik Frejd

Christofer Lendel

Brian James Grimmond

Brian E Green

Nina Herne

Peter Brian Iveson

David A DeGoey

Victoria Eugenia Cotero

Tiberiu Mircea Siclovan

David J Grampovnik

Cristina Abucay Tan Hehir

Bruce Fletcher Johnson

Larry L Klein

Kent D Stewart

Ming Clinton Yeung

Hui-Ju J Chen

Randall Lee Carter

Ernest William Kovacs

Malin Lindborg

Vincent S Stoll

Michael Ernest Marino

William J Flosi

Kande Kankanamalage Dayarathna Amarasinghe

Jeannette Christine Roberts

Tove Eriksson

Kenneth Michael Fish

Hongmei Mo

Wenping He

Nobuhiko Iwasaki

Akhteruzzaman Molla

Sherie V L Masse

Tove Simonsson

Anshika Bajaj

Jeannette Christine DePuy

Omayra Liz Padilla De Jesus

Nicole Evelyn Barnhardt

Sherie Vl Masse

Jennifer Lynne Huntington

Akteruzzaman Molla

Christopher Lendel

Joshua Kendall Hoerner

Laura M Maymon

Qinghua Xie

Omayra Padilla De Jesus

Kande Kankanamalage Amarasinghe

Jennifer Huntington

Keith F Mcdaniel

Kande Kankanamalage Dayara Amarasinghe

Davida Degoey

Jeannette Christine Depuy

ClarenceJ Maring

PamelaL Donner

ToddW Rockway

CurtS Cooper

KeithF Mcdaniel

JohnK Pratt

JasonP Shanley

DaroldL Madigan

DavidA Betebenner

RobertJ Carrick

TamiJ Pilot-Matias

DavidD Anderson

DaleJ Kempf

Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

HER2 binders

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.

Methods of detecting myelin basic protein

Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.

Labeled molecular imaging agents, methods of making and methods of use

A method of diagnostic imaging is disclosed comprising administering a medical formulation to a subject, the formulation comprising a contrast enhancement agent having structure I and salts thereof wherein Ris independently at each occurrence a hydroxy group, a C-Chydroxyalkyl group, or a C-Calkyl group, and b is 0-4; R-Rare independently at each occurrence hydrogen, a C-Chydroxyalkyl group, or a C-Calkyl group, with the proviso that at least one of R-Ris a hydroxy group or a C-Chydroxyalkyl group; and wherein Q is one or more charge balancing counterions; and one or more pharmaceutically acceptable carriers and excipients. The subject is subjected to a diagnostic imaging technique such as magnetic resonance imaging. The technique may be used in a variety of diagnostic imaging regimes, such as imaging of circulatory systems, genitourinary systems, hepatobiliary systems, central nervous systems, tumors, and abscesses among others.

Hydroxylated contrast enhancement agents and imaging method

In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I and salts thereof wherein Ris independently at each occurrence a hydroxy group, a C-Chydroxyalkyl group, or a C-Calkyl group, and b is 0-4; R-Rare independently at each occurrence hydrogen, a C-Chydroxyalkyl group, or a C-Calkyl group, with the proviso that at least one of R-Ris a hydroxy group or a C-Chydroxyalkyl group; and wherein Q is one or more charge balancing counterions. Also provided are a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement agent I.

Hydroxylated contrast enhancement agents

The present invention relates to agents capable of binding to myelin basic protein in a subject. Also provided are methods for the detection of myelin-associated neuropathy comprising identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, administering to a subject an agent that binds specifically to myelin basic protein, and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.

Agents and methods for the imaging of myelin basic protein

Methods for introducing fluorine atom onto a polypeptide are provided. Also provided are linkers, bioconjugates, and bifunctional compound agents made using the methods, linkers, and bioconjugates. The methods comprise: (i) providing a linker comprising a thiol-reactive terminus and an aldehyde-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a polypeptide comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the aldehyde-reactive terminus of the linker with a fluorine-substituted aldehyde.

Fluorine-labeled compounds

In one aspect, the present invention provides a protected ligand precursor having structure XX wherein Ris independently at each occurrence a protected hydroxy group, a protected C-Chydroxyalkyl group, or a C-Calkyl group, and b is 0-4; R-Rare independently at each occurrence hydrogen, a protected C-Chydroxyalkyl group, or a C-Calkyl group, with the proviso that at least one of R-Ris a protected hydroxy group or a protected C-Chydroxyalkyl group; and Rand Rare independently at each occurrence a protecting group is selected from the group consisting of C-Caliphatic radicals, C-Ccycloaliphatic radicals, and C-Caromatic radicals.

Intermediates for hydroxylated contrast enhancement agents

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Provided herein are PDGF-R&#x3b2; imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-&#x3b2;. Also provided are in vivo imaging methods using the imaging agents.

PDGF-R&#x3b2; binders

An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of different natural amino acid mutations in the polypeptide are provided here. Also provided are methods of using the two-helix binders.

Two helix binders

An isolated polypeptide, Z domain, derived from B domain ofprotein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of a covalent bridge between two modified amino acids in the polypeptide is provided here. Also provided are methods of using the two-helix binders.

Growing community of inventors

Niskayuna, NY, United States of America

Rong Zhang